Abstract
Hypnotics may be used by athletes to avoid sleep disturbance or insufficient sleep the night before sports events. However, in the past, taking hypnotics for sleep disturbances resulted in an unsuccessful attempt due to residual effects. The purpose of this study is to assess the residual effects of eszopiclone (2 mg), one of the non-benzodiazepine hypnotics, on physical performance, psychomotor function and subjective evaluations in 12 healthy athletes. Eszopiclone did not have serious side effects in athletic evaluations. This medication significantly improved short-term memory test rather than placebo and did not impair any other objective evaluations in athletes. There was no change in well-being and fatigue scales on the following day in the eszopiclone session, but daytime alertness was significantly worsened in the subjective evaluations. Eszopiclone has a hypnotic activity without disturbing psychomotor and physical performance on the following day when given to healthy adults, suggesting eszopiclone may be used in healthy athletes to adjust their extrinsic sleep disturbances and their consecutive psychomotor and physical impairments.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Leger D, Guilleminault C, Dreyfus JP, Delahaye C, Paillard M. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res. 2000;9:35–42.
Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6:97–111.
Kim K, Uchiyama M, Okawa M, Liu X, Ogihara R. An epidemiological study of insomnia among the Japanese general population. Sleep. 2000;23:41–7.
Altena E, Van Der Werf YD, Strijers RL, Van Someren EJ. Sleep loss affects vigilance: effects of chronic insomnia and sleep therapy. J Sleep Res. 2008;17:335–43.
Fortier-Brochu E, Morin CM. Cognitive impairment in individuals with insomnia: clinical significance and correlates. Sleep. 2014;37:1787–98.
Sateia MJ, Nowell PD. Insomnia. Lancet. 2004;364:1959–73.
Mougin F, Simon-Rigaud ML, Davenne D, Renaud A, Garnier A, Kantelip JP, Magnin P. Effects of sleep disturbances on subsequent physical performance. Eur J Appl Physiol. 1991;63:77–82.
Leger D, Metlaine A, Choudat D. Insomnia and sleep disruption: relevance for athletic performance. Clin Sports Med. 2005;24:269–85 (viii).
Erlacher D, Ehrlenspiel F, Adegbesan OA, El-Din HG. Sleep habits in German athletes before important competitions or games. J Sports Sci. 2011;29:859–66.
Juliff LE, Halson SL, Peiffer JJ. Understanding sleep disturbance in athletes prior to important competitions. J Sci Med Sport. 2015;18:13–8.
Charles RB, Kirkham AJ, Guyatt AR, Parker SP. Psychomotor, pulmonary and exercise responses to sleep medication. Br J Clin Pharmacol. 1987;24:191–7.
Grobler LA, Schwellnus MP, Trichard C, Calder S, Noakes TD, Derman WE. Comparative effects of zopiclone and loprazolam on psychomotor and physical performance in active individuals. Clin J Sport Med. 2000;10:123–8.
Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343.
Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev. 2000;4:551–81.
Ito SU, Kanbayashi T, Takemura T, Kondo H, Inomata S, Szilagyi G, et al. Acute effects of zolpidem on daytime alertness, psychomotor and physical performance. Neurosci Res. 2007;59:309–13.
Ito W, Kanbayashi T, Shimizu K, Ito SU, Shimizu T, Nishino S. Acute effects of zaleplon on daytime functions on the following day—psychomotor and physical performances, arousal levels and mood. Gazz Med Ital Arch Sci Med. 2017;176(5):257–64.
Tafti M, Besset A, Billiard M. Effects of zopiclone on subjective evaluation of sleep and daytime alertness and on psychomotor and physical performance tests in athletes. Prog Neuropsychopharmacol Biol Psychiatry. 1992;16:55–63.
Hindmarch I, Patat A, Stanley N, Paty I, Rigney U. Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. Hum Psychopharmacol. 2001;16:159–67.
Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343.
Smith JM, Misiak H. Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects-a review. Psychopharmacologia. 1976;47:175–82.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors do not have any conflict of interest for this paper.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Akita University Ethical Committee and with the 1964 Helsinki Declaration and its later amendments.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Suda, H., Kanbayashi, T., Ito, S.U. et al. Residual effects of eszopiclone on daytime alertness, psychomotor, physical performance and subjective evaluations. Sleep Biol. Rhythms 15, 311–316 (2017). https://doi.org/10.1007/s41105-017-0112-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s41105-017-0112-z